NetworkNewsBreaks Archive - Page 1991 of 2081

ThursdayMay 11, 2017 12:53 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Zogenix, Inc. (NASDAQ: ZGNX)

Following Zogenix’s (NASDAQ: ZGNX) first-quarter results, Aegis Capital has reiterated its ‘Buy’ rating and price target of $28 on shares of the company’s stock. Zogenix reported total revenue for the first quarter of $2.7 million, consisting entirely of contract manufacturing revenue. Additionally, Zogenix recently said it has completed enrollment in Study 1, the first phase 3 clinical trial evaluating ZX008 as an adjunctive treatment for seizures in children and young adults with Dravet syndrome. Top-line data from Study 1 is anticipated in the third quarter of 2017. The company is currently enrolling for 1504, the second pivotal phase 3 trial in…

ThursdayMay 11, 2017 12:52 pm

NetworkNewsBreaks – Aegis Capital Issues “Buy” Rating on CytoSorbents Corp. (NASDAQ: CTSO)

Aegis Capital has issued a ‘Buy’ rating and price target of $9 on CytoSorbents Corp. (NASDAQ: CTSO) following the company’s report of financial and operational results for the quarter ended March 31, 2017. The company reported total revenues of $3.1 million for the first quarter of 2017, which includes both product sales and grant income. This represents an increase of 72% from revenues of $1.8 million from the same period of the previous year. The analyst noted the company’s plan to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval of its flagship CytoSorb® blood filter as well as plans to expand…

ThursdayMay 11, 2017 12:50 pm

NetworkNewsBreaks – Synthesis Energy Systems, Inc. (NASDAQ: SYMX) Locks In Technology License Agreement for Project in Australia; Shares Climb

Synthesis Energy Systems (“SES”) (NASDAQ: SYMX) shares ticked 8% higher after the company said it has entered into a definitive Technology License Agreement with Australian Future Energy Pty Ltd ("AFE") for a large-scale project to be located in Australia. Per the agreement, SES will collect fees based on the licensed capacity for the project, and for the Process Design Package (PDP), totaling $27 million. Additionally, the entire package of technology, services and equipment is anticipated to provide SES with revenue of approximately $150 million. The company will immediately begin providing technical services to AFE related to the development of the…

ThursdayMay 11, 2017 11:09 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Pursues Continued Success in CBD Markets

Leveraging its achievements of amassing a 100,000+ user base, establishing a recognizable 18-year-old brand, and sharpening its focus on a market that exceeds two billion Chinese-speaking individuals, ChineseInvestors.com (OTCQB: CIIX) has reached a first-in-the-marketplace milestone by launching the world’s first and only Chinese language, cannabinoid-based therapeutic health products web store, http://www.ChineseCBDoil.com. After making a successful investment in the marijuana market, the company recently expanded into the retail and online sale of cannabidiol (CBD), which has become one of the fastest-growing market categories in the United States. “With an annual growth rate of nearly 60 percent, CBD oil has become one…

ThursdayMay 11, 2017 11:07 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Poised to Become Phytocannabinoid Pharmaceuticals Leader

At its recent 70th annual meeting, the American Epilepsy Society (AES) highlighted a study focusing on the potential of cannabidiol (CBD) to treat the frequency and severity of seizures in children who have drug-resistant epilepsies. India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures. “Cannabidiol is the most abundant non-psychoactive cannabinoid found…

WednesdayMay 10, 2017 1:58 pm

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends Role of “Father of Marijuana Research” Raphael Mechoulam

In a news release issued early Tuesday, ABcann Global Corporation (TSXV: ABCN) announced that Raphael Mechoulam has agreed to extend his role as an advisor to the company. Aaron Keay, CEO and director of ABcann, spoke to the importance of this agreement in the news release. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history,” he stated. “The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has…

WednesdayMay 10, 2017 12:51 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 10, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MNKD 49.11% – News: Hosting earnings call at 5 p.m. ET MTBC 34.49% – News: Posts Q1 2017 results ARGS 21.71% – News: Provides update on the ADAPT trial BXNG 19.94% – News: Gifts cost of unique wedding at Denver church PESI 12.50% – News: Posts Q1 2017 results ECIA 12.50% – News: Posts Q4 fiscal 2017 results MIHI 9.50% – News: Issues shareholder update SORL 8.21% – News: Releasing Q1 2017 results May…

WednesdayMay 10, 2017 12:49 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on Recro Pharma, Inc. (NASDAQ: REPH)

Aegis Capital has issued a ‘Buy’ rating and price target of $11 on Recro Pharma (NASDAQ: REPH) following the company’s recent report of positive top-line results from its phase 3 safety study evaluating intravenous (IV) meloxicam following major surgery. The analyst noted that the final clinical requirement was met for the IV Meloxicam NDA, and the company is on track to file in the third quarter of 2017. Shares of Recro Pharma are currently trading at $7.57 with a 52-week range of $0.59-$12.50. For more information, visit www.recropharma.com About Recro Pharma, Inc. Recro is a specialty pharmaceutical company that operates…

WednesdayMay 10, 2017 12:47 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating on Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is…

WednesdayMay 10, 2017 12:44 pm

NetworkNewsBreaks – Proteon Therapeutics, Inc.’s (NASDAQ: PRTO) Vonapanitase Receives Breakthrough Therapy Designation by FDA; Shares Soar

Proteon Therapeutics (NASDAQ: PRTO) shares are up 35% this morning on news that vonapanitase has received Breakthrough Therapy designation from the FDA. The investigational treatment received the designation for increasing arteriovenous fistula secondary patency (i.e., survival of the fistula without abandonment) and use for hemodialysis in patients on or expected to initiate hemodialysis. Secondary patency and fistula use for hemodialysis are also the co-primary endpoints of the company’s ongoing pivotal phase 3 clinical trial, PATENCY-2. Enrollment in the trial is anticipated to be complete in the first quarter of 2018, and the company expects top-line data in the first quarter…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks